Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.

Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 1994Cited by 40 (Europe PMC)

PMID8154311DOI10.1002/jbmr.5650090110PepBankPUB-08154311

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In early postmenopausal women, calcitonin plus calcium improved bone density evolution versus calcium alone from 6 months onward (p < 0.01).
In plain wordsIn early postmenopausal women, calcitonin plus calcium preserved bone density better than calcium alone from 6 months onward.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar bone density trajectory
Study
n = 186
Comparator
Calcium alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU/day, 5 days per week · intranasal · 3 yearsAs given in this study (human).
Measurements
P value for difference in BMD evolution
< 0.01
calcitonin plus calcium versus calcium alone
Source sentences
Summary
The difference between the evolution of the two groups was significantly (p < 0.01) different after 6 months of treatment and remained so until the end of the study.
3 context sentences(design, population, supporting numbers)
Summary · context
The average changes in bone mineral density after 36 months showed a positive (p < 0.05) outcome (1.8 +/- 5.7%; mean +/- SD) in the group treated with salmon calcitonin and calcium and a significant (p < 0.01) loss (-5.8 +/- 4.8%) in patients receiving calcium alone.
Summary · context
Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism.
Summary · context
The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin.
Report a problemFND-0815431102
02HumanNon-randomized trialEfficacy outcome
In early postmenopausal women receiving calcium, calcitonin increased lumbar bone density by 1.8 +/- 5.7% after 36 months (p < 0.05).
In plain wordsIn early postmenopausal women receiving calcium, lumbar bone density increased with calcitonin after 36 months.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar bone density change at 36 months
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU/day, 5 days per week · intranasal · 3 yearsAs given in this study (human).
Measurements
Lumbar spine BMD change at 36 months
1.8%
salmon calcitonin plus calcium
SD of lumbar spine BMD change at 36 months
5.7%
salmon calcitonin plus calcium
Source sentences
Summary
The average changes in bone mineral density after 36 months showed a positive (p < 0.05) outcome (1.8 +/- 5.7%; mean +/- SD) in the group treated with salmon calcitonin and calcium and a significant (p < 0.01) loss (-5.8 +/- 4.8%) in patients receiving calcium alone.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism.
Summary · context
The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin.
Report a problemFND-0815431101
03HumanNon-randomized trialEfficacy outcome
In early postmenopausal women, no significant changes occurred in biochemical bone turnover parameters during the calcitonin study.
In plain wordsIn early postmenopausal women, bone turnover markers did not change significantly during the calcitonin study.
Peptide
Calcitonin-salmon
Outcome
No significant changeBiochemical bone turnover parameters
Study
n: not reported in source
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
50 IU/day, 5 days per week · intranasal · 3 yearsAs given in this study (human).
Source sentences
Summary
No significant changes were recorded in biochemical parameters reflecting bone turnover.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism.
Summary · context
The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin.
Report a problemFND-0815431103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.